Antibiotics, Antineoplastic
"Antibiotics, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
| Descriptor ID |
D000903
|
| MeSH Number(s) |
D27.505.954.248.106
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibiotics, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antibiotics, Antineoplastic".
This graph shows the total number of publications written about "Antibiotics, Antineoplastic" by people in this website by year, and whether "Antibiotics, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibiotics, Antineoplastic" by people in Profiles.
-
Disrupting the feed-forward cycle of RyR1 Ca2+ leak and oxidative stress mitigates doxorubicin-induced skeletal myopathy. Am J Physiol Cell Physiol. 2026 07 01; 331(1):C59-C73.
-
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866.
-
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 04 07; 323(13):1266-1276.
-
Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. J Geriatr Oncol. 2020 04; 11(3):463-469.
-
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
-
Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. Endocrinology. 2013 Oct; 154(10):3937-46.
-
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7.
-
rhBMP-2 enhancement of posterolateral spinal fusion in a rabbit model in the presence of concurrently administered doxorubicin. Spine J. 2007 May-Jun; 7(3):326-31.
-
Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. Lancet Oncol. 2005 Feb; 6(2):67.
-
Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells. J Clin Immunol. 2004 Sep; 24(5):553-60.